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Radiotherapyusedinthetreatment ofpediatric musculoskeletalsarcomasmayresultincripplingdefects ofskeletalgrowth.Several
radioprotective strategies have shown potential for preserving function of the irradiated epiphysis but have not been evaluated
in a tumor-bearing animal model. We developed two bioluminescent human rhabdomyosarcoma cell lines that were used to
establish xenograft tumors in skeletally immature mice. Bioluminescence imaging and radiography allowed serial evaluation of
tumorgrowth and tibial elongation followinglocalized radiotherapy. High-dose (10Gy) radiotherapy signiﬁcantlyreduced tumor
growth velocity and prolonged the median survival of tumor-bearing mice but also resulted in a signiﬁcant 3.3% shortening of
the irradiated limb. Exposure to a lower, 2Gy dose resulted in 4.1% decrease in limb length but did not extend survival. This new
model provides a clinically relevant means to test the eﬃcacy and safety of novel radioprotectant and radiorecovery strategies for
use in this context.
1.Introduction
Rhabdomyosarcoma is the most common pediatric soft-
tissue sarcoma [1]. It is a malignant tumor thought to
derive from the skeletal muscle lineage that primarily aﬀects
young children and adolescents, and very rarely adults [2].
A multimodal approach to rhabdomyosarcoma treatment is
favored, where surgical excision and chemotherapy are used
in conjunction with external-beam radiotherapy to achieve
tumor eradication [3, 4]. Skeletal complications including
limb length asymmetry, crippling angular deformity, and
pathologic fracture may result when the irradiated ﬁeld is
inclusive of the epiphyseal growth plate [5, 6]. Laboratory
studies have demonstrated the eﬃcacy of radioprotectant
compounds such as amifostine in reducing the injurious
eﬀects of ionizing radiation to the skeletal growth plate, but
due to the lack of a clinically relevant, tumor-bearing animal
model have not yet been tested for use in this context [7–9].
Commonly,preclinicaltestingofantitumorandsupport-
ive therapies involve inoculation of human tumor cell lines
into immunocompromised murine hosts [10]. The utility
of this approach is further enhanced by the application
of in vivo molecular imaging technologies, allowing serial
assessment of response to experimental treatments. In this
report, we have developed a model system for the study
of pediatric rhabdomyosarcoma in general and the evalu-
ation of adverse bystander eﬀects of radiotherapy on the
skeletal growth plate in particular. The speciﬁc aims of the
current study were to (1) establish variants of two widely-
studied rhabdomyosarcoma cell lines, which stably express a
luciferase tracer, (2) use these cells to develop an orthotopic
xenograft model of rhabdomyosarcoma in NCr nude mice2 Sarcoma
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Figure 1: Luciferin uptake and signal stabilization. Biolumines-
cence imaging wasused to verify tumor placement three hours after
(a) subcutaneous or (b) intramuscular inoculation of RD-luc cells.
Imagingwas initiated one-minute followinga single, 150mg/kgI.P.
bolus of d-luciferin mice, and photon ﬂux data was collected in
successive one minute intervals. (c) Average log-photon ﬂux ±1SD
of n = 4 mice demonstrating a detectable signal within 1 minute
following luciferin injection and was stable for a period ranging
from 10 to 24 minutes after-injection. No signal was detected in
animals injected with cell-free Matrigel.
that allows the evaluation of tumor progression by biolumi-
nescence imaging, and (3) to document the adverse skeletal
sequelae of irradiating an orthotopic tumor in growing
mice. It was hypothesized that intramuscular rather than
subcutaneous implantation of human rhabdomyosarcoma
tumor cells would result in more robust tumor engraftment
and growth. We then hypothesized that the use of external
beam radiotherapy would reduce orthotopic tumor growth
and prolong survival. It was anticipated that the irradiation
of the tumor bed and the adjacent epiphyseal growth plate
would result in signiﬁcant limb length asymmetry.
2.Methods
2.1. Rhabdomyosarcoma Tumor Cell Lines. Two well-estab-
lished rhabdomyosarcoma cell lines were used in this series
of experiments. The embryonal variant is represented in our
studies by the cell line RD (ATCC# CCL-136, Manassas, Va,
USA). The cell line RC13, also referred to variably in the
literature as SJCRH30, RC-13, RMS 13, SJRH30, or RH30
(ATCC #CRL-2061), is representative of the alveolar variant.
Both cell lines were cultured in DMEM, supplemented
with 10% v/v heat-inactivated fetal calf serum, 4.5mg/mL
glucose, 4mM L-glutamine, 50IU/mL penicillin, 50μg/mL
streptomycin, 10mM HEPES, and 1mM sodium pyruvate.
All cell culture products were obtained (from CellGro,
Manassas, Va, USA). Both cell lines express MyoD1 and
myogenin at the transcript and protein level, which are
markers of early myogenic diﬀerentiation but that are absent
in mature skeletal muscle. The RC13 cells also express a
fusion transcript corresponding to the t(2:13) translocation
joining the Pax3 and FOXO1 (formerly Fkhr) genes that
areadiagnosticcharacteristic ofalveolarrhabdomyosarcoma
[11].Forvalidationpurposes, immunochemistry wasusedto
verify the expression of these markers at the protein level in
both cell lines, while RT-PCR was used to demonstrate and
verify the expression of the Pax3:FKHR fusion transcript in
the RC13 cells (data not shown).
2.2. Transfection and Selection of Bioluminescent Rhabdomyo-
sarcoma Lines. Lipofectamine LTX/Plus (Invitrogen, Carls-
bad, Calif, USA) was used to transfect 1×105 RD or
RC-13 cells with the 10μg of plasmid vector pEGFP-Luc
(Clontech, Mountainview, Calif, USA). This vector allows
the expression of enhanced green ﬂuorescent protein:ﬁreﬂy
luciferase (EGFP-Luc) fusion protein under the control
of the human cytomegalovirus (CMV) promoter element
and allows antibiotic selection with G418 by virtue of a
neomycin-resistance cassette regulated by an SV40 pro-
moter. Following transfection, cells were plated in 10cm
dishes and incubated in growth media supplemented with
500μg/mL G418 for 10 days to select neomycin-resistant
clones. Individual colonies of each transfected cell line were
isolated, examined for EGFP ﬂuorescence, harvested with
trypsin, and expanded for 10 passages in the presence of
200μg/mL G418 to establish stable expression of the EGFP-
Luc fusion protein, yielding the clones RD-Luc and RC13-
Luc. Prior to inoculation into murine hosts, we veriﬁed
the expression of the EGFP-Luc fusion transcript by RT-
PCR, EGFP expression by epiﬂuorescence microscopy, and
luciferase activity by an in vitro luciferase assay system
( P r o m e g a ,M a d i s o n ,W i s ,U S A ) .F o rx e n o g r a f te x p e r i m e n t s ,Sarcoma 3
tumorcellsweregrowntoapproximately50–75%conﬂuence
prior to harvesting with 0.05% trypsin/0.53mM EDTA,
centrifuged,andresuspendedinHank’sbuﬀeredsaltsolution
(HBSS) at 1 × 108 cells/mL. This suspension was further
diluted by the addition of an equal volume of ice-cold HBSS
or ice-cold growth-factor reduced matrigel (BD Biosciences,
San Jose, Calif, USA), and incubated on ice until inoculation
into animal hosts.
2.3. Murine Xenograft Experiments. All experimental pro-
cedures involving the use of animals were performed in
accordance with a protocol approved by the local IACUC. A
total of n = 66 weanling (21 days old) homozygous male
NCr nude mice (CrTac:NCr-Foxn1nu, Taconic Farms Inc.,
Germantown, NY, USA) were obtained for all studies and
randomized to experimental groups as detailed in Table 1.
During routine husbandry, all mice were maintained in
an aseptic isolation colony in groups of n = 3m i c ep e r
cage, with 12-hour light/dark cycles and ad libitum access
to sterilized chow and water. Anesthesia during tumor
inoculation was by an intraperitoneal injection of a com-
bination of tiletamine and zolazepam (Telazol, 15mg/kg;
Fort Dodge Animal Health, Fort Dodge, Iowa, USA). For
ectopic inoculations, anesthetized animals were positioned
prone, and a 22-gauge needle was inserted subcutaneously
over the right ﬂank and swept to create a pocket prior to
the delivery of 20μL of the cell suspension. For tumor-na¨ ıve
animals, an equivalent cell-free suspension was prepared and
held on ice prior to injection. For orthotopic intramuscular
inoculations, themouse waspositioned supine with theright
limb extended; the anterior-distal quadriceps was palpated,
and 20μL of the cell suspension was delivered through a
22g needle inserted into the thigh musculature. Following
inoculation,animalswerereturnedtotheircagesandallowed
to recover from the anesthetic. Two mice from the sham-
irradiated control group succumbed during anesthesia; no
other complications or infections were observed. Subse-
quently, the mice were monitored daily for general health
and well-being. On a weeklybasis, animals were weighed and
examined by palpation of the inoculation site and ipsilateral
lymph nodes. General malaise, weight loss greater than 10%,
or tumor mass approximating 20% of body weight was
criteria for euthanization in accordance with institutional
protocol.
2.4. In Vivo Bioluminescence Imaging. Imaging studies were
performed immediately after inoculation and on a weekly
b a s i st h e r e a f t e ru s i n gt h eI V I S-50 instrument (Caliper Life
Sciences, Hopkinton, Mass, USA). The mice were anes-
thetized by isoﬂurane inhalation, and injected intraperi-
toneally with 150mg/kg d-Luciferin potassium salt dissolved
in normal saline (Caliper). An initial calibration experiment
demonstrated that the luciferase signal reached a plateau,
approximately 8–10 minutes following d-luciferin injection,
and remained stable for at least 14 minutes thereafter
(Figure 1). All subsequent imaging studies were initiated
10 minutes following the injection of d-luciferin, with
photon ﬂux (photons/second) data collected for a period of
5 minutes. Imaging data analysis was performed using Living
Image v3.2 software (Caliper Life Sciences).
2.5. External Beam Radiotherapy. Prior to irradiation, mice
were anesthetized with anintraperitoneal injectionofTelazol
(15mg/kg) and positioned on a Plexiglas platform with the
right leg, inclusive of the tumor bed, extended through a
2cm× 4cm collimated radiation ﬁeld. Lead shielding was
used to protect the remainder of the body from direct
or scattered radiation. The animals were then positioned
beneath the radiation unit (Phillips MGC-30, Farmington,
Conn, USA) at a source-to-skin distance of 30cm, deliv-
ering 300kVp/10mA X-rays, at an eﬀective dose rate of
2.56Gy/min. Groups of n = 6 mice received single exposures
of either 2Gy or 10Gy, with the remaining n = 4m i c ei nt h e
0Gy control group anesthetized and positioned in the same
manner as their irradiated cohort.
2.6. Ex Vivo Analyses of Normal and Tumor Tissues. At the
conclusion of the experimental period, or when physical
examination warranted humane termination, animals were
euthanized by CO2 inhalation, and death was veriﬁed by the
absence of a cardiac pulse. The visceral organs and lymph
nodes were examined grossly for systemic dissemination,
and aﬀected tissues were preserved in 10% neutral buﬀered
formalin. Tumor tissues were excised, and segments were
ﬁxed in 10% neutral buﬀered formalin for histology and
immunohistochemistry. Tissues adjacent to the inoculation
sitewereprocessedsimilarly formicewherenotumorgrowth
was evident. Following excision of the tumor tissue, the
hind limbs were disarticulated at the hip, radiographed
in the sagittal plane, and ﬁxed in 10% neutral buﬀered
formalin. After 24 hours of ﬁxation at 4C, the tissues were
rinsed in phosphate-buﬀered saline and decalciﬁed with
daily changes of 10% EDTA over a period of two weeks.
Subsequently, all tissues were dehydrated through ascending
ethanol series, cleared in xylene, and embedded in paraﬃn.
Tissue sections were then cut at 5μmt h i c k n e s sa n ds t a i n e d
with hematoxylin and eosin for histopathologic examination
or probed with antibodies directed against human myogenin
(#sc-319434, Santa Cruz Biotechnology, Santa Cruz, Calif,
USA) or myoD1(#ab16148 AbCam, Cambridge Mass, USA)
antigens following retrieval in boiling citrate buﬀer. Positive
immunoreactivity was subsequently detected with a biotiny-
lated secondary antibody (Vectastain ABC Elite-Universal,
Vector Labs Burlingame, Calif, USA) and visualized by
ImmPRESS DAB histochemistry, Vector Labs, Burlingame,
Calif, USA).
Baseline and terminal lengthsof thetibia and femurwere
measured for each mouse in the radiotherapy experiment,
from radiographs taken prior to inoculation and immedi-
ately following euthanasia. Femoral length was measured
perpendicular to a line extending from the inter-condylar
notch distally and through the apex of the greater trochanter
proximally. Tibial length was measured perpendicular to a
line extending from the apex of the tibiotalar cup distally to
the center of the tibial plateau proximally. Limb length was
then taken as the sum of the tibia and femur measurements4 Sarcoma
Table 1: Experimental design: IM: intramuscular inoculation; SQ: subcutaneous inoculation; HBSS: Hank’s buﬀered salt solution; Inoc.:
approximate number of cells inoculated; RTX: radiationtherapy; Gy: Gray, units of absorbed radiation;Term.: day of study when mice were
euthanized; EOS: end of study; TB: euthanized due to tumor burden.
Cell line N Location Media Inoc. RTX Engraftment Term. Reason
RD 8 IM HBSS 1 × 106 —0 / 68 4 d E O S
RD 8 IM HBSS 1 × 105 —0 / 68 4 d E O S
RD 8 IM HBSS 1 × 104 —0 / 68 4 d E O S
RD-Luc 4 SQ Matrigel 1 × 106 —4 / 46 4 d E O S
RD-Luc 4 IM Matrigel 1 × 106 —4 / 46 4 d E O S
—2 S Q M a t r i g e l — — 0 / 26 4 d E O S
—2 I M M a t r i g e l — — 0 / 26 4 d E O S
RC13-Luc 6 SQ Matrigel 1 × 106 —5 / 64 3 d T B / E O S
RC13-Luc 6 IM Matrigel 1 × 106 — 6/6 35–43d TB/EOS
RC13-Luc 4 IM Matrigel 1 × 106 0Gy 4/4 56–64d TB
RC13-Luc 6 IM Matrigel 1 × 106 2Gy 6/6 57–64d TB
RC13-Luc 6 IM Matrigel 1 × 106 10Gy 6/6 57–84d TB/EOS
for each animal, and growth was taken as the diﬀerence in
length between the initial and terminal lengths.
2.7. Statistical Analysis. Raw photon ﬂux (p/s) data were
log-transformed prior to statistical analysis. Diﬀerences in
limblengthbetweenirradiated andnonirradiated limbswere
assessed by the Student’s paired t-test, and ANOVA was used
to examine diﬀerences between the radiation-dose groups,
accepting diﬀerences as statistically signiﬁcant when P ≤
.05. Median survival time after-inoculation was evaluated
by Mantel-Cox Log-Rank test. All statistical analyses were
performed using StatView software v5.01 (SAS Institute,
Cary, NC, USA).
3.Results
3.1. Comparison of TumorEngraftment and Growth in Ectopic
versusOrthotopicLocations. EngraftmentofRDcellsinjected
as a suspension in an aqueous vehicle at titers of 1 ×
104,1× 105,o r1× 106 cells/mouse did not result in any
detectabletumorengraftment by palpation orbyhistological
examination of the inoculated musculature or ipsilateral
lymphatic chain tissues in a 12-week pilot study. The failure
to achieve engraftment using aqueous media prompted our
decision to suspend the tumor cells in Matrigel. To further
enhance our ability to detect occult tumors and metastases,
we established stably transfected variants of two human
rhabdomyosarcoma cell lines expressing ﬁreﬂy luciferase,
RD-luc, and RC13-luc, to permit the use of bioluminescence
imaging. This approach allowed the visualization of the
tumor cell mass as early as three hours after inoculation
(Figure1).Theseadaptationsgreatlyimprovedthelikelihood
of detectable engraftment to greater than 97% (Table 1).
3.2. Bioluminescence Imaging Facilitates Tumor Localization
and Measurement. We then followed the growth rate of
xenografts derived from inoculation of RD-luc or RC13-luc
cells suspended in Matrigel when inoculated in an ectopic
(subcutaneous) or orthotopic location (intramuscular).
Regardless of the location, RD-luc cells persisted at the
inoculation site but failed to produce signiﬁcant (P>. 2667)
tumor growth by 9 weeks after inoculation (Figures 3(a)–
3(c)). Luminescence of the orthotopically placed RD-Luc
cells was signiﬁcantly greater (P = .0172) than ectopic
subcutaneous tumors at 26 days after inoculation, but
diﬀerences at all other time points were not statistically
signiﬁcant (P>. 2470).
By contrast, orthotopic inoculation of the RC13-Luc cell
line formed a rapidly growing tumor, outwardly evident by
14 daysafter inoculation and necessitating humane euthana-
sia as early as 35 days after inoculation (Figures 3(d)–3(f)).
RC13-Luc inoculation into the thigh musculature resulted
in signiﬁcantly larger tumors at each weekly time-point
following inoculation (P>. 0055) when compared to RC13-
Luc cells inoculated subcutaneously.
At the end of study, necropsies were performed and
tumor tissues were preserved for histological examination.
Ectopic inoculation of either cell line produced a ﬁrm,
poorly vascularized mass that was loosely associated with
subcutaneous fascia. Orthotopic inoculation of RD-luc cells
produced small, ﬁrm tumors that were conﬁned to the inoc-
ulated muscle compartment. In contrast, orthotopic inoc-
ulation of RC13-luc cells produced tumors that were inﬁl-
trating the underlying musculatureand displayed prominent
superﬁcial vascularization, with regions of cystic necrosis
centrally. Both cell lines demonstrated histological features,
respectively, corresponding to the implanted embryonal
or alveolar variants of rhabdomyosarcoma, including nests
of small round blue cells with ﬁbrovascular septae and
positive MyoD1 and Myogenin immunochemistry. Injection
of cell-free Matrigel into either location did not produce
any signs of neoplasia, infection, inﬂammation, or lymph
node enlargement and was not evident on histological
examination of local tissues retrieved at the end of study.
3.3. Radiotherapy Inhibits Tumor Growth and Prolongs
Survival but Results in Limb Length Asymmetry. LocalizedSarcoma 5
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Figure 2: Serial bioluminescence imaging RC13-luc xenografts following radiotherapy with 0Gy, 2Gy, or 10Gy X-rays. All animals in
the 0Gy and 2Gy groups were euthanized within 63 days of imaging. (a) Data presented as the mean log-transformed photon-ﬂux
(photons/second) ±1SD;bracketsindicateP ≤ .05 by ANOVA with Bonferroni-Dunn post hoc test. Representative images demonstrating
tumor localizationand growth in (b) nonirradiated, (c) 2Gyirradiated, and (d) 10Gy irradiated mice.
ionizing radiation therapy (0, 2, or 10Gy X-rays at 300kVp)
was administered to the tumor-bearing limb over a ﬁeld
encompassing the distal femoral and proximal tibial growth
plates. The remainder of the body including the non-
tumor-bearing limb was protected from direct and scattered
radiation by beam collimation and lead shielding. For
our experiments, radiotherapy was initiated one week after
inoculation, immediately following the demonstration of
successful tumor engraftment by bioluminescence imaging.
Prior to irradiation, no signiﬁcant diﬀerences were observed
between dose groups (Figure 2(a)). Nonirradiated tumors
displayedaggressivegrowthnecessitatinghumaneeuthanasia
of all mice in this group within 64 days of inoculation.
Localized radiotherapy of orthotopic RC13-Luc xenografts
resulted in a dose- and time-dependent suppression of
tumor growth (Figures 2(c) and 2(d)). Bioluminescence of
tumors exposed to 2Gy X-rays was signiﬁcantly reduced in
comparison to the sham-irradiated group through 42 days
after inoculation, In contrast to the sham-irradiated group,
10Gy irradiation signiﬁcantly suppressed tumor growth
through 49 days after inoculation. Statistically signiﬁcant
diﬀerences between the 2Gy and 10Gy groups were only
apparent one week following radiotherapy.
Aggressive tumor growth necessitated the termination
of all mice in the sham-irradiated and 2Gy-irradiated
groups between 56 and 64 days after inoculation (Figure 4).
Necropsy showed gross evidence of metastatic dissemination
inthreemicefromthesham-irradiated group:oneassociated
with the right kidney, one along the ureter, and one
attached to the chest wall superior to the xiphoid. These
distant masses appeared histologically consistent with the
primary tumor and also displayed positive MyoD1 and
myogenin immunoreactivity. (Figures 4(a)–4(d)) Four mice
from the 10Gy-irradiated group were euthanized due to
tumor burden from days 56–77 after inoculation; however
two mice from the 10Gy-irradiated group presented only a
locally contained lesion at 84 days without a sign of systemic
dissemination. Median survival of sham-irradiated (range
56–64) and 2Gy- (range 57–64) irradiated mice was 63 days
after inoculation and was not signiﬁcantly diﬀerent (P =
.7390). Median survival of 10Gy irradiated mice (77 days,
range 57–84 days) was signiﬁcantly longer than that of non-
radiated mice (P = .0224) (Figure 4(e)).
Irradiation of the tumor bed and the underlying knee
region inclusive of the distal femoral and proximal tibial
growth plates, resulted in a reduction of the length of the6 Sarcoma
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Figure 3: Serial bioluminescence imaging demonstrating successful tumor engraftment resulting from subcutaneous and intramuscular
inoculation of RD-luc and RC13-luc tumor cells. (a) The growth of RD-luc tumors did not demonstrate substantial tumor growth when
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Figure4:Representative histologyandimmunohistochemistryofRC13-lucderivedmetastaticlesion.(a)H&E,10x,and(a)40x;(b)MyoD1;
(c) IHC neg. control; (d) Myogenin. (e) Cumulative survival. Kaplan-Meier plot of survival in tumor-bearing mice following localized
irradiation with 2Gy (solid black) or 10Gy X-rays (dotted blue), or 0Gy, sham-irradiated mice.
irradiated limbs relative to the contralateral, nonirradiated
limbs as measured from contact radiographs (Table 2). The
average total length of the tumor-bearing limb of mice
receiving radiotherapy wassigniﬁcantly reducedwith respect
to the contralateral control by 1.2 ± 0.2mm (P = .0007)
for the 2Gy-treated mice and 0.9 ± 0.03mm (P = .0067) in
10Gy-irradiated mice. In contrast, the 0.3 ± 0.4mm average
diﬀerence between the control and tumor-bearing limbs in
the sham-irradiated group was not signiﬁcant (P = .3769).
The total length of the nonirradiated limbs of 10Gy-treated
mice (30.4 ± 0.6mm) was greater than that of the 2Gy
(29.1 ± 0.7mm, P = .0049) and nonirradiated controls
(28.6 ± 0.8mm, P = .0015). Similarly, the tumor-bearing
irradiated limb of the 10Gy group (29.4 ± 0.8mm) was
signiﬁcantly longer than the tumor-bearing limb in either
the nonirradiated control group (28.6 ± 0.8mm, P = .0404)
or the 2Gy-irradiated group (27.9 ± 0.6mm, P = .0044).
We attribute the greater terminal length of the both the
nonirradiated control and 10Gy-irradiated limbs to the
elongation accumulated during the extended survival period
in comparison to the nonirradiated and 2Gy groups.
4.Discussion
4.1. Model Development and Reﬁnement. Subcutaneous
inoculation of the tumor cells is a classical approach used8 Sarcoma
Table 2: Terminal femur, tibial, and total limb length. Data shown are mean ±1SD; ‡diﬀerences between control and irradiated, tumor-
bearing limbs were accepted as signiﬁcantwhen P ≤ .05 by Student’s paired t-test.
Femur length (mm) Tibia length (mm) Limb length (mm)
Control Irradiated Control Irradiated Control Irradiated
0G y
Mean ± SD 13.5 ± 0.6 13.2 ± 0.5 15.1 ± 0.6 15.1 ± 0.8 28.6 ± 0.8 28.3 ± 0.9
P‡ P = .0892 P = .6467 P = .3769
2G y
Mean ± SD 13.4 ± 0.4 12.8 ± 0.6 15.6 ± 0.4 14.9 ± 0.4 29.1 ± 0.7 27.9 ± 0.6
P‡ P = .0141 P = .0156 P = .0072
10Gy
Mean ± SD 14.3 ± 0.4 13.8 ± 0.6 16.1 ± 0.3 15.6 ± 0.3 30.4 ± 0.6 29.4 ± 0.8
P‡ P = .0013 P = .0123 P = .0003
to study the in vivo response of the tumors to experimental
therapies. The translational relevance of ectopic xenograft
studies can be problematic, as the placement of tumor
cells into a physiologically foreign environment may not
faithfully recapitulate the physiologic microenvironment of
the primary lesion, adjacent nonneoplastic stromal and
parenchmyal cells, or local vasculature [12–16]. Similarly,
intravenous andintracardiac injection models fail toaccount
for the initial events that lead to metastasis and so fail to
appreciate the importance of this aspect of tumor biology.
Further, the response of an ectopic tumor to systemic or
localized therapies may not realistically resemble that of a
malignancy in its primary tissue of origin [17]. For these
reasons,orthotopicplacementisrapidlygainingfavoramong
cancer researchers, but this approach is not without limita-
tion. Orthotopic placement can require invasive procedures
to achieve the engraftment and assessment of tumor growth
in situ. This limitation can therefore require a large number
of subjects to achieve statistical signiﬁcance due to terminal
data collection. Further, this approach can be relatively
insensitive to occult lesions and systemic dissemination,
which are essential to understanding this most critical aspect
of cancer biology and treatment.
O u rp r i m a r yo b j e c t i v ei nt h i ss e r i e so fe x p e r i m e n t sw a s
to developan orthotopic xenograft model that would permit
parallel examination of tumor and epiphyseal responses to
radiotherapy. Our initial attempts to establish an orthotopic
tumor by injection of tumor cells in an aqueous suspen-
sion were not fruitful. In all likelihood, this reﬂected a
failure of engraftment, which was addressed in subsequent
reﬁnement of our model. The enhancement of graft success
by Matrigel suspension has been previously reported for a
wide variety of tumor cell types [18, 19]. Our subsequent
experimentsinvolvedsuspension ofrhabdomyosarcoma cells
in a Matrigel basement matrix, which greatly enhanced
tumor engraftment in comparison to aqueous inoculation
media (Figure 1,T a b l e1). The precise mechanism by which
the artiﬁcial matrix improves tumor cell survival and growth
remains unclear but may involve sequestration from NK
cells or induction of angiogenesis at the site of tumor
implantation [20, 21]. There was no gross or microscopic
evidence of residual Matrigel at 64 days following injection.
Similarly, no residual matrix was observed in the tumor
b e do fm i c ei n o c u l a t e dw i t hR Do rR C 1 3c e l l sa t8 4d a y s ,
suggesting that the matrix is resorbed in a manner that is
independent of the presence of tumor cells.
A second objective in developing this model was to mea-
sure tumor response to experimental therapies with the long
term goal of testing complementary radioprotective agents
with thismodel.Tumorgrowthcanbeassessed bymeasuring
the dimensions of an externally evident tumor but are
relatively insensitive and fail to account for occult lesions or
systemic dissemination. The application of bioluminescence
imaging technology, as demonstrated recently by Comstock
et al. [22], and reviewed by Michelini et al. [23], greatly
enhances the ability to measure orthotopic tumors in deep
or inaccessible locations. Studies by Jenkins et al. [24]a n d
Lim etal.[25]havedemonstratedthatluminescenceimaging
of tumor burden is much more sensitive to occult tumors
than palpation or other external evidence. Previous work by
Seitz et al. established a xenograft model involving alveolar
rhabdomyosarcoma cells stably transfected to express the
DSred2 ﬂuorescent protein [26] for localization of subcu-
taneously inoculated tumors. However, this earlier study
quantiﬁedtumorburdenusingexternalphysicaldimensions,
rather than the ﬂuorescence signal intensity, presumably due
to limits on the depth of penetrence of the excitation and
emission wavelengths. Further, these luminescence-imaging
systems allowed more precise quantitation of tumor burden
than physical examination and were sensitive to decreases
in tumor signal due to various physiological manifestations,
including focal tumor necrosis.
With these considerations in mind, we established two
rhabdomyosarcoma cell lines which stably expressed ﬁreﬂy
luciferase for use developing our xenograft model. We
demonstrated that bioluminescence imaging is a useful
modality for verifying tumor placement, engraftment, and
subsequent evaluation of tumor growth and treatment
response, as has been demonstrated for a wide variety of
other solid tumors (reviewed in [25]). Through the use of
this technology, we were able to serially quantify tumor
growthand response totreatment. Further, wedemonstrated
that RC13-luc derived tumors are sensitive to a single high-
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4.2. Comparison of Embryonal and Alveolar Rhabdomyosar-
coma Xenografts. We observed little growth of RD-luc
embryonal rhabdomyosarcoma tumors in either inoculated
site (Figures 3(a)–3(c)), and there were no lesions suggestive
of metastatic dissemination observed. Embryonal rhab-
domyosarcoma variants tend to be somewhat less aggressive
and are frequently associated with small muscles of the
head, neck, orbit, and genitourinary tract of infants and
young children, features that our model did not replicate.
Orthotopic placement of a xenograft tumor was hypothe-
sized to improve upon ectopic approaches as a more faithful
replication of the physiologic conditions experienced in situ.
Consistent with this hypothesis, we observed that orthotopic
inoculation of RC13-luc alveolar rhabdomyosarcoma cells
into the distal thigh musculature resulted in a much more
aggressive tumor growth than when compared to subcu-
taneous inoculation (Figures 3(d)– 3(f)). Further, distant
metastases were apparent in 3 of 16 nonirradiated mice
bearing RC13-luctumorssuggesting that the inoculated cells
were competent for systemic dissemination (Figures 4(a)–
4(d)). Alveolar-variant rhabdomyosarcoma tends to be the
more aggressive subtype, most frequently arising from the
large muscles of the appendicular skeleton, adjacent to the
growth plate of older children and adolescents. Each of
these features was replicated in the mice bearing orthotopic
tumors derived from the RC13-luc cell line. Diﬀerences
in microenvironmental physiology including autocrine [27–
29] or paracrine signals [30, 31], local hemodynamics, and
tumor hypoxia [32, 33]a te i t h e rs u b c u t a n e o u so ro r t h o t o p i c
inoculation site may be an important consideration but were
not examined as contributing factors in this pilot study.
4.3. Radiation-Induced Physeal Bystander Eﬀect in a Tumor-
Bearing Animal Model. This model also allows examination
oftheclinicalmorbiditysyndromeoflimblengthasymmetry
and angular deformity that can occur when oncologic
therapy mandates irradiation of an open physis. Using
this model, we showed that the growth plate was sensitive
to 2Gy or 10Gy radiation doses, producing signiﬁcant
limb length asymmetry. Of particular note was our ﬁnding
that both limbs from the high-dose group were longer at
termination than either of the sham-irradiated or 2Gy-
irradiated cohorts. We interpret this observation simply as
a result of the prolonged survival associated with the higher
radiotherapy dose. This supports previous observations
reported in a rat model of unilateral radiation-induced limb
length asymmetry [8, 34, 35]. suggesting that despite the
initial growth plate injury, the growth plate retains some
capacity for regeneration. These are important ﬁndings that
support the clinical relevance of this small animal model
for testing the safety and eﬃcacy of radioprotectant and
recovery-stimulating strategies.
Certain limitations of this new model are evident but
may be reﬁned or modiﬁed to suit speciﬁc experimental
applications in future work. For example, it is accepted those
this model in its current inception deviates from clinical
best practice standards of fractionated radiotherapy with
45–56Gy administered as a series of 1.8–2Gy exposures
[36, 37]. Future reﬁnements to address this limitation would
be anticipated to resemble that observed previously in an
analogous rat model developed by our laboratory, wherein
a fractionated radiotherapy protocol would produce a more
subtle reduction in limb length than an equivalent single
exposure [38, 39]. Anotherpotential limitation to this model
is the question of whether xenograft models using immuno-
compromised host mice are immunologically relevant. This
limitation is much more diﬃcult to address, given the
propensity for graft rejection in intact animals. Recent work
[40, 41] demonstrating the spontaneous development of
rhabdomyosarcoma tumors in mice with somatic PTCH1
haploinsuﬃciency suggests which may provide an ideal
model to study rhabdomyosarcoma biology. However such
a model may further complicate parallel studies of skeletal
growth given the central role that PTCH1 plays in regulating
growth plate chondrocyte biology. Despite these limitations,
the current model appears to be a reasonable and clinically
relevant means to study the role of novel complementary
therapies, which will be explored in future work.
5.Conclusions
This series of experiments describes the development of a
new orthotopic xenograft model of rhabdomyosarcoma for
the study of tumor and bystander responses to radiotherapy.
This work also presents variants of two well-established
rhabdomyosarcoma cell lines which stably express ﬁreﬂy
luciferase, allowing the use of in vivo bioluminescent imag-
ing. Using this model system, we were able to demonstrate
responses of tumor cells and bystander tissues that reason-
ably resemble clinical outcomes. We anticipate that this new
model will be a valuable tool in evaluating the eﬃcacy and
safety of novel radioprotectant and radiorecovery strategies
prior to their use in human clinical trials.
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